US NeutroSpec labelling under review after serious ADR reports.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Subject Terms:
      MALLINCKRODT Inc. 047021092 MKG; PALATIN Technologies Inc. 153575733
    • Abstract:
      This article reports on a letter issued by pharmaceutical companies Mallinckrodt and Palatin Technologies Inc. to advise of postmarketing reports of the side effects of the drug NeutroSpec. Several NeutroSpec-associated cardiopulmonary events are mentioned. The recommendations of the companies to patients experiencing the adverse reactions are cited.